N-phenylacetyl-L-prolylglycine ethyl ester, brand name Noopept, is promoted as a nootropic and is a prodrug of cycloprolylglycine.

It was synthesized in Russia in 1996, is orally available, and as of 2017 its metabolism and half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.

It is apparently about 1,000 times more potent than piracetam. As of 2017 there had been many studies conducted in cells and in animal models, and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.